Recruiting Immune Cells. In addition to stimulating T cells, BsAbs such as blinatumomab and catumaxomab that target CD3, CD19, and EpCAM also guide these cells toward cancer cells, where they can lead to lysis them (4). The gene discussed is CD19; the disease is cancer.